Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Matthew Krebs, Alexander I. Spira, Byoung Chul Cho, Benjamin Besse, Jonathan W. Goldman, Pasi A. Janne, Zhiyong Ma, Aaron Scott Mansfield, Anna Rachel Minchom, Sai-Hong Ignatius Ou, Ravi Salgia, Zhijie Wang, Casilda Llacer Perez, Grace Gao, Joshua C Curtin, Amy Roshak, Robert W. Schnepp, Meena Thayu, Roland Knoblauch, Chee Khoon Lee
Institutions: University of Manchester, The Christie NHS Foundation Trust, Yonsei University, Yonsei Cancer Hospital, Institut Gustave Roussy, Fondation Gustave Roussy, University of California, Los Angeles, Dana-Farber Cancer Institute, Henan Cancer Hospital, Mayo Clinic, Institute of Cancer Research, University of California, Irvine Medical Center, City Of Hope National Medical Center, Chinese Academy of Medical Sciences & Peking Union Medical College, State Key Laboratory of Molecular Oncology, Hospital Clínico Universitario Virgen de la Victoria, St George Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4281750842